Biosimilar

Palivizumab Biosimilar Pipeline Development Service

Comprehensive Solutions for RSV F protein-Targeted Biosimilar Development

Creative Biolabs provides end-to-end development solutions for Palivizumab biosimilars, guiding clients through every phase from initial analytical assessment to final regulatory filing. Leveraging extensive experience in antibody design and RSV F protein targeting technologies, we ensure a scientifically robust and compliant pathway through the biosimilar development process.

At a glance of Palivizumab

Service Overview

Palivizumab is a humanized monoclonal antibody specifically designed to target the fusion (F) protein of respiratory syncytial virus (RSV), a key factor in viral entry into host cells. By binding to a highly conserved epitope on the F protein, Palivizumab effectively neutralizes the virus and prevents infection of respiratory epithelial cells. It is widely used for the prevention of severe RSV disease in high-risk pediatric populations, including premature infants and those with chronic lung or congenital heart conditions. Engineered to combine human and murine antibody elements, Palivizumab demonstrates reduced immunogenicity and favorable pharmacokinetic properties, making it a valuable tool in RSV prophylaxis.

Basic Information

Drug Type: Monoclonal antibody

Synonyms: Palivizumab (Genetical Recombination), Palivizumab (genetical recombination) (JAN), Palivizumab (USAN/INN)

Target: RSV F protein

Action: Inhibitors

Mechanism: Respiratory syncytial virus F protein inhibitors

Inactive Indication: Aortic Coarctation; Chronic lung disease; Ductus Arteriosus, Patent

Originator Organization: AbbVie, Inc.

Inactive Organization: Abbott Laboratories; AbbVie, Inc.; MedImmune LLC

First Approval Date: United States (19 Jun 1998)

Most Recent Events

Date	Events
17 Dec 2024	Merck Announces Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season
17 Dec 2024	Merck Announces Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

Pipeline Status

Our Palivizumab Biosimilar Pipeline Offers

Fig.1 Palivizumab Biosimilar Pipeline. (Creative Biolabs Original)

Development Workflow of Palivizumab Biosimilar Pipeline

Early Development & Analytical Characterization
1	Project Initiation & Feasibility Assessment	Market and intellectual property (IP) landscape analysis Reference product sourcing and preliminary evaluation Regulatory strategy planning based on target markets (e.g., EMA, NMPA)
2	Analytical Characterization	Physicochemical profiling (e.g., mass spectrometry, peptide mapping) Structural and functional comparability assessment Glycosylation pattern and impurity analysis Binding affinity and neutralization activity testing
3	Cell Line Development	Host cell line selection (e.g., CHO) Transfection and clone screening Stability studies and productivity assessment Cell bank establishment (Master Cell Bank, Working Cell Bank)
4	Process Development	Upstream: Optimization of culture conditions and bioreactor parameters Downstream: Purification process development (Protein A, ion exchange, etc.) Scale-up studies and tech transfer readiness
5	Formulation Development	Excipient screening and stability optimization Compatibility and container-closure system evaluation Final drug product specification setting
Non-Clinical Development
6	Preclinical Studies	In vitro biological activity testing Pharmacokinetics and toxicology evaluation in relevant models Comparability to reference Palivizumab

Available Packages

Creative Biolabs provides customizable and scalable service solutions tailored to support every phase of your Palivizumab biosimilar development journey. Whether you're initiating analytical comparability studies or approaching regulatory submission, you can select from modular service options aligned with your specific project stage—or work with us to design a fully personalized development plan.

Items	classification	What we can offer
1	Antibody Product	Fully characterized Palivizumab biosimilar antibody available in research-grade or GMP-grade formats, suitable for analytical testing and preclinical studies.
2	Cell Line	High-producing, stable CHO cell line expressing the biosimilar antibody, with detailed documentation including clone selection history, productivity profiles, and stability data.
3	Analytical & Biological Data	Physicochemical Analysis Structural Analysis Functional Bioactivity Impurity and Purity Profile Non-Clinical Data In Vitro Studies In Vivo Studies

Why Choose Us

Integrated Development Platform

End-to-end services covering antibody production, cell line development, and comprehensive analytical characterization—all under one roof.

High Quality & Customization

Stable high-yield CHO cell lines, research- and GMP-grade antibodies, and flexible service packages tailored to your project stage and goals.

Expertise You Can Trust

Decades of antibody engineering experience with strong capabilities in biosimilarity assessment, ensuring scientific precision and efficient progress.

Ready to Advance Your Palivizumab Biosimilar Program

Contact us to explore how we can create a personalized development strategy aligned with your regulatory objectives and project schedule. Reach out today to request a quote, book a consultation, or access our detailed service brochure.

For research use only. Not intended for any clinical use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.